Open AccessFeasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review
Author(s) -
Rumeng Gu,
Ziling Shi,
Ting Duan,
Meijun Song
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s334213
Subject(s) - alectinib , anaplastic lymphoma kinase , medicine , adenocarcinoma , crizotinib , alk inhibitor , lung cancer , oncology , tyrosine kinase inhibitor , cancer , malignant pleural effusion
Pulmonary invasive mucinous adenocarcinoma (IMA) is a rare variant of lung adenocarcinoma that rarely shows anaplastic lymphoma kinase (ALK) rearrangement. Alectinib (tyrosine kinase inhibitors) has been listed as category 1 recommendations for advanced ALK + NSCLC first-line therapy due to low toxicity and excellent efficacy, and its median progression-free survival is 34.8 months. Here, we report a case of a patient with ALK-rearranged lung IMA who showed favorable results to neoadjuvant alectinib.